SCHEMBL1051982

SCHEMBL1051982

CC(C)(C)n1nccc1Nc1cccc(CC2(c3n[nH]c(=O)o3)CCN(C(=O)c3cccc(Cl)c3F)CC2)n1

nearest known ligand 0.56

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
AURKA O14965 20/20 0.56
AURKB Q96GD4 20/20 0.56
INCENP Q9NQS7 8/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12931295 0.93 AURKA (0.49) AURKAAURKBINCENP
SCHEMBL1057496 0.91 AURKA (0.51) AURKAAURKBINCENP
SCHEMBL1054611 0.90 AURKA (0.58) AURKAAURKBINCENP
SCHEMBL1057136 0.87 AURKA (0.71) AURKAAURKBINCENP
SCHEMBL1055640 0.85 AURKA (0.57) AURKAAURKBINCENP
SCHEMBL16361727 0.84 AURKA (0.45) AURKAAURKBINCENP
SCHEMBL1052430 0.84 AURKA (0.44) AURKAAURKBINCENP
SCHEMBL1055752 0.83 AURKA (0.53) AURKAAURKB
Trifluoroacetic Acid SCHEMBL1055248 0.82 AURKA (0.53) AURKAAURKBINCENP
SCHEMBL12931302 0.82 AURKA (0.46) AURKAAURKBINCENP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180369224-A1 NOVEL PIPERIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-12-27 US disclosed
US-10092556-B2 Piperidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-10-09 US disclosed
US-20160228427-A1 NOVEL PIPERIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
EP-2821406-B1 NOVEL PIPERIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2016-06-01 EP disclosed
US-9346787-B2 Piperidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2016-05-24 US disclosed
US-20150045342-A1 NOVEL PIPERIDINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-02-12 US disclosed
EP-2821406-A1 NOVEL PIPERIDINE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2015-01-07 EP disclosed
EP-2254888-B1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION MSD KK (JP) 2014-12-24 EP disclosed
EP-2254888-B1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION MSD KK (JP) 2014-12-24 EP disclosed
US-8519136-B2 Aminopyridine derivatives having aurora a selective inhibitory action MSD K.K. (JP) 2013-08-27 US disclosed
US-8519136-B2 Aminopyridine derivatives having aurora a selective inhibitory action MSD K.K. (JP) 2013-08-27 US disclosed
US-8519136-B2 Aminopyridine derivatives having aurora a selective inhibitory action MSD K.K. (JP) 2013-08-27 US disclosed
US-20110003833-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-01-06 US disclosed
US-20110003833-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-01-06 US disclosed
US-20110003833-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-01-06 US disclosed
EP-2254888-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION Banyu Pharmaceutical Co., Ltd. (JP) 2010-12-01 EP disclosed
WO-2009104802-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-08-27 WO disclosed
WO-2009104802-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10092556-B2 Piperidine compound or salt thereof TUBB6, KIF5A, TUBB3 AURKA 7/4885AURKB 30/4885INCENP 504/4885
US-20180369224-A1 NOVEL PIPERIDINE COMPOUND OR SALT THEREOF CBR3, PRMT6, PRMT5 AURKA 3455/4885AURKB 3610/4885INCENP 4038/4885
US-20110003833-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION AURKA, AURKC, AURKB AURKA 1/4885AURKB 3/4885INCENP 88/4885
US-20150045342-A1 NOVEL PIPERIDINE COMPOUND OR SALT THEREOF KIF5A, TUBB6, AURKC AURKA 5/4885AURKB 21/4885INCENP 490/4885
US-20160228427-A1 NOVEL PIPERIDINE COMPOUND OR SALT THEREOF KIF5A, TUBB6, AURKC AURKA 5/4885AURKB 21/4885INCENP 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.